U.S. Markets close in 4 hrs 22 mins
  • S&P 500

    3,443.68
    +16.76 (+0.49%)
     
  • Dow 30

    28,341.69
    +146.27 (+0.52%)
     
  • Nasdaq

    11,507.33
    +28.45 (+0.25%)
     
  • Russell 2000

    1,624.24
    +10.61 (+0.66%)
     
  • Crude Oil

    40.66
    -0.17 (-0.42%)
     
  • Gold

    1,912.30
    +0.60 (+0.03%)
     
  • Silver

    24.86
    +0.17 (+0.68%)
     
  • EUR/USD

    1.1827
    +0.0054 (+0.4613%)
     
  • 10-Yr Bond

    0.7820
    +0.0210 (+2.76%)
     
  • Vix

    29.33
    +0.15 (+0.51%)
     
  • GBP/USD

    1.2961
    +0.0020 (+0.1581%)
     
  • USD/JPY

    105.5620
    +0.1320 (+0.1252%)
     
  • BTC-USD

    11,973.85
    +916.84 (+8.29%)
     
  • CMC Crypto 200

    241.03
    +2.11 (+0.88%)
     
  • FTSE 100

    5,896.65
    +12.00 (+0.20%)
     
  • Nikkei 225

    23,567.04
    -104.09 (-0.44%)
     

Aurinia Completes Final Patient Treatment in Dry Eye Study

Zacks Equity Research
·3 mins read

Aurinia Pharmaceuticals Inc. AUPH announced that it has completed the last patient study visit in the phase II/III AUDREY study evaluating voclosporin ophthalmic solution (VOS) for the potential treatment of dry eye syndrome (DES). Dry eye syndrome is a chronic autoimmune disorder affecting the quality of life for millions in the United States.

The primary outcome measure for the study is the proportion of subjects with a 10mm improvement in Schirmer’s Tear Test (STT) at four weeks. Secondary outcome measures include STT at 12 weeks and other time points, Fluorescein Corneal Staining (FCS) at multiple time points, change in eye dryness, burning/stinging, itching, photophobia, eye pain and foreign body sensation at multiple time points, change in Symptom Assessment in Dry Eye (SANDE) score at multiple time points, and additional safety endpoints.

Shares of the company have lost 29.1% compared with the industry’s decline of 7.6%.

In January 2019, Aurinia reported that although VOS (voclosporin 0.2%) administered twice daily did not meet the primary endpoint of drop discomfort at oneminute, it was superior to Allergan’s AGN Restasis (0.05% cyclosporine A) administered twice daily in all objective endpoints, including FCS and STT. The statistical superiority was seen as quickly as two weeks. Thus, the company believes that VOS represents a potential best-in-class calcineurin inhibitor in ophthalmic indications.

Top-line results from the AUDREY clinical study are expected to be reported during the fourth quarter of 2020.

Zacks Rank &Stocks to Consider

Aurinia currently carries a Zacks Rank #3 (Hold).

Some better-ranked stocks in the healthcare sector include Emergent Biosolutions Inc. EBS and Bio Techne Corp TECH. While Emergent Biosolutions sports a Zacks Rank #1 (Strong Buy), Bio Techne carries a Zacks Rank #2 (Buy) . You can see the complete list of today’s Zacks #1 Rank stocks here.

Emergent’s earnings estimates have increased from $4.23 to $6.58 for 2020 and from $5.55 to $7.62 for 2021 over the past 60 days. Shares of the company have increased 92.1% year to date.

Bio Techne’s earnings estimates have increased from $5.33 to $5.48 for 2020 and from $6.41 to $6.50 for 2021 over the past 60 days. Shares of the company have increased 11.0% year to date.

Aurinia Pharmaceuticals Inc Price

Aurinia Pharmaceuticals Inc Price
Aurinia Pharmaceuticals Inc Price

Aurinia Pharmaceuticals Inc price | Aurinia Pharmaceuticals Inc Quote

Just Released: Zacks’ 7 Best Stocks for Today

Experts extracted 7 stocks from the list of 220 Zacks Rank #1 Strong Buys that has beaten the market more than 2X over with a stunning average gain of +24.3% per year. These 7 were selected because of their superior potential for immediate breakout.

See these time-sensitive tickers now >>


Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
 
Emergent Biosolutions Inc. (EBS) : Free Stock Analysis Report
 
BioTechne Corp (TECH) : Free Stock Analysis Report
 
Aurinia Pharmaceuticals Inc (AUPH) : Free Stock Analysis Report
 
To read this article on Zacks.com click here.
 
Zacks Investment Research